Topic: MS

Disease activity-free rates at 1 and 2 years

March 23, 2013  

Second-line switching: three reports

March 23, 2013  

CCSVI: has the balloon burst?

March 23, 2013  

BG-12: two analyses of safety results

March 22, 2013  

Natalizumab update: anti-JCV Ab testing and PML risk

March 22, 2013  

Brain atrophy reduced with fingolimod

March 22, 2013  

Pregnancies may slow disability progression

March 21, 2013  

Update on treatment trials: teriflunomide, daclizumab and CombiRx

March 21, 2013  

Effect of NaCl on pathogenic Th17 cells

March 21, 2013  

Application to FDA for first-line natalizumab

March 13, 2013